200 related articles for article (PubMed ID: 19879974)
21. A two-stage dose selection strategy in phase I trials with wide dose ranges.
Wang O; Faries DE
J Biopharm Stat; 2000 Aug; 10(3):319-33. PubMed ID: 10959914
[TBL] [Abstract][Full Text] [Related]
22. Design issues in dose-finding Phase I trials for combinations of two agents.
Fan SK; Venook AP; Lu Y
J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
[TBL] [Abstract][Full Text] [Related]
23. Retrospective robustness of the continual reassessment method.
O'Quigley J; Zohar S
J Biopharm Stat; 2010 Sep; 20(5):1013-25. PubMed ID: 20721788
[TBL] [Abstract][Full Text] [Related]
24. Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit.
Whitehead J; Zhou Y; Stevens J; Blakey G; Price J; Leadbetter J
Stat Med; 2006 Jan; 25(1):37-53. PubMed ID: 16342336
[TBL] [Abstract][Full Text] [Related]
25. Adaptive design may hasten clinical trials.
Schmidt C
J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
[No Abstract] [Full Text] [Related]
26. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.
Zohar S; Chevret S
J Biopharm Stat; 2003 Feb; 13(1):87-101. PubMed ID: 12635905
[TBL] [Abstract][Full Text] [Related]
27. Methods of joint evaluation of efficacy and toxicity in phase II clinical trials.
Tournoux C; De Rycke Y; Médioni J; Asselain B
Contemp Clin Trials; 2007 Jul; 28(4):514-24. PubMed ID: 17331808
[TBL] [Abstract][Full Text] [Related]
28. Statistical designs for early phases of cancer clinical trials.
Guan S
J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
[TBL] [Abstract][Full Text] [Related]
29. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
Daimon T; Zohar S; O'Quigley J
Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
[TBL] [Abstract][Full Text] [Related]
30. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
Morita S
Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
[TBL] [Abstract][Full Text] [Related]
31. Bayesian model averaging continual reassessment method for bivariate binary efficacy and toxicity outcomes in phase I oncology trials.
Asakawa T; Hirakawa A; Hamada C
J Biopharm Stat; 2014; 24(2):310-25. PubMed ID: 24605971
[TBL] [Abstract][Full Text] [Related]
32. Two-dimensional dose finding in discrete dose space.
Wang K; Ivanova A
Biometrics; 2005 Mar; 61(1):217-22. PubMed ID: 15737096
[TBL] [Abstract][Full Text] [Related]
33. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
Hirakawa A
Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
[TBL] [Abstract][Full Text] [Related]
34. Dose-finding in phase I clinical trials based on toxicity probability intervals.
Ji Y; Li Y; Nebiyou Bekele B
Clin Trials; 2007; 4(3):235-44. PubMed ID: 17715248
[TBL] [Abstract][Full Text] [Related]
35. Dose selection in phase I studies: why we should always go for the most effective.
Haines IE
J Clin Oncol; 2008 Jul; 26(21):3650-2; author reply 3652-3. PubMed ID: 18640947
[No Abstract] [Full Text] [Related]
36. Dose selection in phase I studies: why we should always go for the top.
Sleijfer S; Wiemer E
J Clin Oncol; 2008 Apr; 26(10):1576-8. PubMed ID: 18332465
[No Abstract] [Full Text] [Related]
37. Improved designs for dose escalation studies using pharmacokinetic measurements.
Piantadosi S; Liu G
Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
[TBL] [Abstract][Full Text] [Related]
38. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence].
Kusaba H; Tamura T
Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451
[TBL] [Abstract][Full Text] [Related]
39. Dose finding with continuous outcome in phase I oncology trials.
Wang Y; Ivanova A
Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
[TBL] [Abstract][Full Text] [Related]
40. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.
Doussau A; Asselain B; Le Deley MC; Geoerger B; Doz F; Vassal G; Paoletti X
Contemp Clin Trials; 2012 Jul; 33(4):657-65. PubMed ID: 22521954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
